Porzingis, POTS and the NBA's Repricing of Availability

The most memorable moment of Kristaps Porzingis's 2026 summer involved no basketball. It was a short notification, the kind NBA reporters post at midnight Vietnam time: he would miss the start of the season because of an undisclosed health matter. Days later, Shams Charania named the condition — postural orthostatic tachycardia syndrome, POTS. I read that on my phone, in a cafe along the Han River in Da Nang, and I found myself thinking about a line I wrote years ago about an League of Legends final: a dynasty does not collapse with thunder, it collapses with one slipped step in the final minute of stoppage time. Here, that slipped step lasts 82 games, and there is no slow-motion replay to watch. A 2.21-metre man, 30 years old, at the stage where his skill set is most complete, suddenly has to answer a question no training academy prepares a player for: does my body still permit me to do this job? Porzingis was born in August 2026, is Latvian, stands somewhere between 2.18 and 2.21 metres depending on the measurement source, and is one of the few players above 2.15 metres who both shoots enough threes and blocks enough shots to belong in the NBA's unicorn category. His career averages sit around 19 to 20 points, seven to eight rebounds and close to two blocks per game, with true shooting in the low 60s across recent seasons. POTS is a form of autonomic nervous system dysfunction, not the classical autoimmune disease many aggregations describe. Its three signature symptoms are a sharp heart-rate spike when moving from lying or sitting to standing, persistent fatigue, and impaired recovery after exertion. For a professional athlete, that third symptom is the frightening one — it does not take away the jump shot, it takes away the ability to recover after the jump shot. In the same news cycle, a separate report said the Golden State Warriors were exploring trade routes and that Porzingis was weighing his future in basketball. His contract is expiring, in the region of 30 million dollars. That is the full set of facts required for analysis, and also the full set that needs verification: public records I cross-checked place Porzingis in Atlanta after the 2026 offseason, so the team attribution in the circulating report deserves a second look before anyone quotes it. On first hearing, this is a medical story. For someone who reads basketball for a living, it is a valuation story. The stretch-five archetype — a centre who shoots threes and drags the opposing centre out of the paint — stopped being avant-garde long ago; Brook Lopez and Myles Turner normalised it. Porzingis did not invent the model. He is its most extreme version: a 2.21-metre frame, enough three-point volume that defenders must respect it, and a block rate among the league leaders. The scarcity is in the combination, not the idea. Offensively, he is a gift to a movement-heavy system like Golden State's. A 2.21-metre player an opposing guard is not allowed to leave at the arc bends the entire help rotation. His pick-and-pop creates driving lanes for guards; his pick-and-roll lob turns an ordinary pass into points. Defensively the picture is far worse: he protects the rim well in drop coverage, but he is a poor fit for a scheme that demands constant switching. A 2.21-metre body with a lower-body injury history cannot be the piece in a switch-everything defence. This is where I want to slow down, because it is the familiar blind spot of every trade report. Porzingis's tactical value rises in the playoffs in theory — spacing matters more, rim protection matters more — and falls in practice. The playoffs are where opposing guards hunt him through every screening action, where contact thickens, where an eight-man rotation compresses and every minute on the floor is audited. His most recent postseason sample showed a sharply reduced role and reduced minutes, and that reduction matches a physical limitation better than a tactical choice. Based on my experience covering games across nine seasons, in both basketball and esports, one metric always misleads: the per-game average. The correct frame is value per season, not value per game. A player producing 20 points, eight rebounds and two blocks across 45 games adds roughly the same wins as a player producing 14, nine and 1.5 across 70. Porzingis's career availability sits in the 55 to 65 percent range, with wide year-to-year variance. Any valuation that uses per-game numbers without an availability multiplier will overpay substantially. At 30, he is in the transition between prime and early decline. Normally a skill-first player — shooting, length, timing — ages more gracefully than an explosiveness-first one. Porzingis belongs to that group, so he should have had a few extra years. That protection is neutralised here, because the constraint is not leaping ability but systemic recovery capacity. Add a dense lower-body history — ACL reconstruction, meniscus, calf, ankle, foot — plus a systemic condition, and he lands in the high-variance, low-floor bucket: real ceiling if managed, and a non-trivial probability of zero contribution. One inference I want to label clearly as an inference, not a clinical conclusion: POTS involves blood pooling downward on standing, and that stress scales with standing height. A 2.21-metre athlete is a physiologically unfavourable host for this condition. If he returns, opponents will target him with pace and repeated screening actions — not because he defends poorly, but because a capped minute count creates a fourth-quarter absence window. Behind the court, the operating problem is harder still. An expiring contract worth around 30 million dollars is a useful salary-matching instrument in any negotiation, and a liability if a team wants to retain him long term. Golden State is a repeat taxpayer bound by apron thresholds, meaning the ability to aggregate salaries to match a 30 million dollar deal is tightly restricted, and every extra dollar is multiplied by the tax rate. Their stock of future first-round picks is also depleted after years of win-now trades. Added together, fair value for a 30-year-old on an expiring deal with an uncertain medical base is salary filler plus at most one protected first-round pick or a swap. If the medical outlook is genuinely severe, that value can turn negative, meaning the selling side must add a sweetener. The most consequential legal instrument here is the Disabled Player Exception. If a player is expected to be unavailable through roughly mid-June, a team may apply for an exception worth the lesser of 50 percent of the player's salary and the non-taxpayer mid-level amount, subject to league physician review. The process is not automatic. It also carries a communications side effect: filing is a public signal of pessimism, so teams often delay — and the absence of a filing is not evidence of a good prognosis. In the locker room, the risk is not drama. A roster with veteran leadership and a long-tenured superstar usually handles this better than a young one. The risk is drift — a team waiting on a medical answer instead of committing to an identity. The head coach has to build two parallel plans, with him and without him, and the price of building in parallel is a training camp split in half. At the wider level, this is a shock to a small basketball nation. Latvia does not have many players at this level; a 2.21-metre star missing FIBA windows changes both the ambition and the commercial value of the national programme. At league level, it is one more data point pushing the market toward a conclusion long in formation: availability is the scarcest skill. And here is where I have to remind myself of an occupational trap. I tend to write about the loser before the winner, and that instinct easily turns a medical case into a tragic ballad. Sympathy is not permitted to distort facts. Porzingis is not a talented player abandoned by a system. He is a top-tier player with a health problem, and that problem is not about the quality of his craft. The contrarian angle sits elsewhere. Coverage will ask whether he comes back, when the more important question is at what role and what workload. A player used for 20 to 24 matchup-selected minutes can still generate positive value. A player paid as a 30-minute pillar cannot. And the circulating report itself needs careful reading: its team attribution does not reconcile with public records. When an aggregation gets a foundational detail wrong, it should be cited through the original reporter, not through itself. The biggest trap is the narrative of the fighter who came back. That romantic version is precisely what makes teams overpay, then watch their cap sheet lock for two seasons. A career rarely ends on a final whistle; it ends on a morning when you wake up and your heart beats out of rhythm. What I want to keep from this story is not a forecast about a return date. It is a change in how we read a box score: a box score has no column for time spent off the floor, and that is the column that decides things. If the NBA is serious about pricing availability, every model should multiply per-game value by an availability multiplier rather than footnoting it. And for a 2.21-metre man wondering whether his body still permits it — the sport owes him a kinder answer than a midnight tweet.